Astragalus for kidney health has become a growing area of interest in integrative and conventional nephrology alike. Astragalus membranaceus, often called huáng qí in Chinese medicine, has a long history of use in East Asia and is now being studied for its effects on proteinuria, inflammation, oxidative stress, fibrosis, blood pressure, and the decline in kidney function. This blog will focus on the benefits of Astragalus for kidney health. The most encouraging findings suggest that astragalus may have kidney-supportive effects, especially as an add-on rather than a replacement for standard care, but the evidence is still mixed, and the quality of many studies remains uneven.
That balance matters. Some reviews and trials report improvements in creatinine, creatinine clearance, proteinuria, and eGFR trends, while major safety guidance for CKD still warns clinicians to review herbal products carefully because people with kidney disease are more vulnerable to adverse effects, contamination issues, and herb-drug interactions. Astragalus is promising, but it is not yet a guideline-endorsed primary therapy for kidney disease.
By Majd Isreb, MD, FACP, FASN, IFMCP
What Is Astragalus?
Astragalus generally refers to the dried root of Astragalus membranaceus or closely related species used in traditional Chinese medicine. Modern pharmacology identifies several major bioactive groups within astragalus, especially polysaccharides, saponins such as astragaloside IV, and flavonoids. These compounds are thought to contribute to its immunomodulatory, antioxidant, anti-inflammatory, and antifibrotic actions.
From a kidney perspective, that matters because CKD progression is not driven by a single pathway. Albuminuria, hemodynamic stress, inflammation, mitochondrial dysfunction, oxidative injury, endothelial dysfunction, and fibrosis all interact over time. A multi-compound herb that engages several of those pathways simultaneously is one reason astragalus has attracted so much interest in kidney research.
Astragalus for Kidney Health in Traditional and Modern Context
In traditional Chinese medicine, astragalus is often used to support qi, resilience, and recovery. In contemporary nephrology-oriented research, the focus is different: investigators are asking whether astragalus can slow eGFR decline, reduce proteinuria, improve tubular and glomerular injury markers, or complement standard therapies in diabetic kidney disease, membranous nephropathy, and other CKD settings.
The key point is that modern research does not support replacing ACE inhibitors, ARBs, SGLT2 inhibitors, blood pressure control, diabetes management, or immunologic therapies when indicated. Instead, astragalus is mostly being studied as an adjunct to standard care.
What Human Studies Show About Astragalus for Kidney Health
The older Cochrane review on astragalus for CKD included 22 studies with 1,323 participants and found signals of benefit, including improved creatinine clearance, lower serum creatinine, lower 24-hour proteinuria, and higher hemoglobin in some groups. But the review also emphasized that overall study quality was low, risk of bias was common, and key hard outcomes such as mortality or time to dialysis were not reported.
More recently, a 48-week multicenter randomized controlled trial in patients with type 2 diabetes, stage 2 to 3 CKD, and macroalbuminuria found that add-on astragalus slowed the rate of eGFR decline by an estimated 4.6 mL/min/1.73 m² per year compared with standard care alone. The endpoint systolic blood pressure was also lower in the astragalus group, while the change in urine albumin-creatinine ratio was not significantly different between groups. The authors concluded that astragalus stabilized kidney function on top of standard care.
That is one of the more clinically meaningful recent findings because it moves beyond short-term surrogate endpoints. Still, it does not settle the question. It was one trial in a specific CKD subgroup, and broader replication is still needed before astragalus can be treated as an established kidney therapy.
A smaller self-controlled case series in mild-to-moderate CKD also suggested improvements in eGFR after astragalus-containing preparations, but the authors noted major limitations, including a small sample size, lack of an optimal control group, and short follow-up.
Astragalus for Kidney Health and Proteinuria
Proteinuria is one of the most important clinical targets in kidney disease because it is both a marker and a mediator of progression. Across older clinical studies summarized in the Cochrane review, astragalus was associated with a reduction in 24-hour proteinuria, though heterogeneity was high.
There is also a disease-specific interest. A meta-analysis in idiopathic membranous nephropathy reported that astragalus preparations added to immunosuppressive therapy were associated with improved response rates, higher serum albumin, and lower proteinuria and serum creatinine. But the evidence was graded as low quality, and the authors cautioned that the effect size may be overestimated because of reporting bias and limited generalizability outside East Asia.
So the practical interpretation is cautious optimism. Astragalus may help reduce protein leakage in some settings, but the evidence is not strong enough to use it as a stand-alone antiproteinuric strategy, especially when proven therapies already exist.
How Astragalus May Work in the Kidney
Preclinical literature is more robust than the clinical literature. A 2024 systematic review and meta-analysis of 40 animal studies in diabetic kidney disease found that astragalus improved serum creatinine, blood urea nitrogen, urinary albumin excretion, and histologic kidney injury. It also improved oxidative stress markers, reduced inflammatory biomarkers, and lowered fibrosis-related markers such as TGF-β1, CTGF, collagen IV, Wnt4, and β-catenin, while increasing the antifibrotic marker BMP-7.
Those findings are mechanistically important because they line up with the main pathways that drive CKD progression. They suggest that astragalus may act less like a single-target drug and more like a network intervention that influences redox signaling, inflammatory cascades, fibrotic remodeling, metabolic stress, and perhaps glomerular barrier injury.
Astragalus for Kidney Health Through Anti-Inflammatory Effects
Inflammation is central to many kidney diseases, from diabetic kidney disease to immune-mediated glomerular disorders. Experimental studies suggest astragalus compounds can reduce inflammatory signaling, including pathways involving NF-κB and inflammasome-related injury. One 2023 study on astragalus polysaccharide reported improvement in diabetic nephropathy-related kidney injury that was linked to reduced inflammatory responses and attenuation of TLR4/NF-κB signaling.
That anti-inflammatory angle is one reason astragalus keeps reappearing in CKD reviews. A 2025 narrative review of Chinese herbal medicine in CKD highlighted astragalus among the herbs with anti-inflammatory, antioxidant, antifibrotic, and immunomodulatory actions that may help reduce proteinuria and stabilize renal function when integrated with standard therapy.
Join us to end the kidney disease epidemic
Astragalus for Kidney Health Through Antioxidant and Antifibrotic Actions
Oxidative stress and fibrosis are major drivers of irreversible nephron loss. Astragalus appears especially interesting here. The 2024 animal meta-analysis found improved antioxidant expression and reduced fibrosis markers in diabetic kidney disease models.
Separate mechanistic work points toward several active fractions. Astragaloside IV has been widely studied for actions involving autophagy, inflammation, and TGF-β/Smad-related pathways. Broader pharmacology reviews identify polysaccharides, saponins, and flavonoids as major active constituents of astragalus, with antioxidant effects being one of the most consistently described biological themes.
Why does that matter clinically? Because once fibrosis becomes established, kidney recovery becomes much harder. If an adjunctive therapy can meaningfully reduce fibrotic signaling early enough, it could theoretically help preserve function. That remains a hypothesis in humans, but it is one of the strongest scientific rationales behind astragalus research.
Which Kidney Conditions Have Been Studied Most?
The strongest concentration of evidence is in diabetic kidney disease. That includes older clinical meta-analyses, the recent randomized controlled trial, and a large share of the mechanistic animal work.
Astragalus has also been studied in chronic glomerular disease, membranous nephropathy, dialysis populations with residual renal function, and other CKD settings. Some observational and retrospective studies suggest benefits in preserving residual renal function in peritoneal dialysis patients, but these findings are far less definitive than randomized evidence.
There are also preclinical studies in acute kidney injury models, including cisplatin nephrotoxicity and sepsis-associated kidney injury, where astragalus fractions appeared to reduce oxidative damage, mitochondrial dysfunction, and tubular injury. These data are scientifically interesting, but it is fair to say that large randomized controlled trials are still lacking.
Safety, Interactions, and When to Be Careful
This is where caution is essential. The U.S. National Center for Complementary and Integrative Health states that there is insufficient reliable scientific evidence to determine whether astragalus is useful for any health condition, and warns that it may worsen autoimmune disease symptoms and interact with medications that suppress the immune system.
KDIGO’s 2024 CKD guideline specifically advises clinicians to review and limit the use of over-the-counter medications and dietary or herbal remedies that may be harmful to people with CKD. That does not single out astragalus as uniquely dangerous, but it does reinforce a broader principle in conventional nephrology: in CKD, “natural” does not automatically mean safe. Dose, product quality, contamination, kidney clearance, potassium content in mixed formulas, and drug interactions all matter.
Astragalus itself appears to have a relatively favorable liver safety profile. LiverTox notes that it has not been associated with clinically apparent liver injury and is considered unlikely to be a cause of hepatotoxicity. At the same time, LiverTox also notes that commercial products may vary in purity and potency, and the possibility of herb-drug interactions should still be considered. Therefore, it is important for patients taking Atragalus to opt for a high-quality product from a reputable company (such as Gaia Herbs).
For kidney patients, extra caution is reasonable in several settings: autoimmune kidney disease, transplant recipients taking tacrolimus or cyclosporine, pregnancy, breastfeeding, complex polypharmacy, and any advanced CKD patient using multi-herb formulas of uncertain composition.
The Bottom Line on Astragalus for Kidney Health
The best current reading of the evidence is this: astragalus for kidney health is promising, especially as an adjunctive strategy in diabetic kidney disease and proteinuric CKD, but it is not yet proven strongly enough to be treated as standard nephrology care. Human data show encouraging signals, including slower eGFR decline in one recent randomized trial and reductions in proteinuria in older pooled studies, while preclinical data consistently support anti-inflammatory, antioxidant, and antifibrotic effects.
At the same time, the limitations are real. Much of the literature is heterogeneous, many older studies were low quality, preparations are not standardized across trials, and long-term hard outcomes such as dialysis initiation, hospitalization, and mortality remain under-studied.
For patients and clinicians, the most responsible approach is not to dismiss astragalus, but not to oversell it either. It may deserve a place in an integrative kidney framework when used thoughtfully, sourced carefully, and coordinated with a clinician who understands CKD pharmacology, herb-drug interactions, and the patient’s specific disease context.
